Aktienanalyse zu Cardio Diagnostics Holdings Inc (CDIO)CDIOCardio Diagnostics Holdings Inc

Cardio Diagnostics Holdings, Inc. is an artificial intelligence-powered precision cardiovascular medicine company. The Company develops and commercializes a series of products for various types of cardiovascular disease and associated co-morbidities, including coronary heart disease (CHD), stroke, heart failure and diabetes, by leveraging its artificial intelligence (AI)-driven Integrated Genetic-Epigenetic Engine. Its first product, Epi+Gen CHD, is an epigenetics-based clinical blood test capable of assessing near-term (three-year) risk for CHD, and its second product, PrecisionCHD, is an epigenetics-based clinical blood test for the detection of CHD. CardioInnovate360 is a research use only (RUO) solution to support the discovery, development, and validation of biopharmaceuticals for the assessment and management of cardiovascular diseases. HeartRisk is a cardiovascular risk intelligence platform that combines insights from anonymized and aggregated clinical cardiovascular data. It operates in the Healthcare sector (IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES industry).

Cardio Diagnostics Holdings Inc is currently not a strong buy due to its significant losses and declining stock performance. The current price is $1.65, which is 9.8% of its 52-week range, indicating it is near its low of $0.97. Additionally, the company has a negative forward P/E ratio and has reported a year-to-date change of -41.87%. The main risk is its high net losses, with the latest reported net income at -$1,501,468 for Q2 2026, which raises concerns about its financial stability.